In a breakthrough, scientists including one of Indian-origin, have designed a drug candidate that may decrease the growth of tumour cells in breast cancer, an advance that could lead to a new generation of medications to treat a range of diseases.
Researchers from The Scripps Research Institute (TSRI) in the US designed the drug candidate that decreases the growth of tumour cells in animal models in one of the hardest to treat cancers – triple negative breast cancer.
“This is the first example of taking a genetic sequence and designing a drug candidate that works effectively in an animal model against triple negative breast cancer,” said Matthew Disney from TSRI.
“The study represents a clear breakthrough in precision medicine, as this molecule only kills the cancer cells that express the cancer-causing gene – not healthy cells,” said Disney.
“These studies may transform the way the lead drugs are identified – by using the genetic makeup of a disease,” he added.
The study demonstrated that the compound, known as Targaprimir-96, triggers breast cancer cells to kill themselves via programmed cell death by precisely targeting a specific RNA that ignites the cancer.